Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.66 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1652907 | 0.90 | F10 (0.61) | F10DRD2DRD4DRD3F2 | |
| SCHEMBL1651881 | 0.82 | F10 (0.75) | F10F2 | |
| SCHEMBL1652594 | 0.81 | F10 (0.60) | F10F2 | |
| SCHEMBL1651321 | 0.81 | F10 (1.00) | F10 | |
| SCHEMBL1651767 | 0.81 | F10 (0.79) | F10 | |
| SCHEMBL5795587 | 0.79 | F10 (0.55) | F10DRD2DRD4DRD3 | |
| SCHEMBL1653323 | 0.79 | F10 (0.58) | F10DRD2DRD4DRD3F2 | |
| SCHEMBL1653346 | 0.78 | F10 (0.57) | F10F2 | |
| SCHEMBL6381282 | 0.78 | HRH4 (0.68) | F10DRD2DRD4DRD3LOXL2 | |
| SCHEMBL4395182 | 0.77 | F10 (0.60) | F10DRD4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306246-A1 | CROSSLINKED COMPOSITION COMPRISING A CORE/SHELL COPOLYMER, METHOD OF OBTAINING SAME AND USES THEREOF | ARKEMA FRANCE (FR) | 2009-12-10 | — | — | US | claimed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | claimed |
| US-6028142-A | Cross-linked elastomer capable of thermoplastic transformation, method of manufacture and uses thereof | HUTCHINSON (FR) | 2000-02-22 | — | — | US | claimed |
| US-20090306246-A1 | CROSSLINKED COMPOSITION COMPRISING A CORE/SHELL COPOLYMER, METHOD OF OBTAINING SAME AND USES THEREOF | ARKEMA FRANCE (FR) | 2009-12-10 | — | — | US | disclosed |
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090176924-A1 | PULVERULENT COMPOSITION BASED ON CARBON NANOTUBES, METHODS OF OBTAINING THEM AND ITS USES, ESPECIALLY IN POLYMERIC MATERIALS | ARKEMA FRANCE (FR) | 2009-07-09 | — | — | US | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
| CN-1291892-A | Substituted oxoazaheterocyclyl factor Xa inhibitors | AWENTIS PHARMACEUTICAL INC (US) | 2001-04-18 | — | — | CN | disclosed |
| US-6028142-A | Cross-linked elastomer capable of thermoplastic transformation, method of manufacture and uses thereof | HUTCHINSON (FR) | 2000-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | F10 12/4885DRD2 2121/4885DRD4 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.